Literature DB >> 33100916

A single-institutional experience with low dose stereotactic body radiation therapy for liver metastases.

Roman O Kowalchuk1, Michael R Waters1, K Martin Richardson1, Kelly M Spencer1, James M Larner2, C R Kersh1.   

Abstract

AIM: This study reports a single-institutional experience treating liver metastases with stereotactic body radiation therapy (SBRT).
MATERIALS AND METHODS: 107 patients with 169 lesions were assessed to determine factors predictive for local control, radiographic response, and overall survival (OS). Machine learning techniques, univariate analysis, and the Kaplan-Meier method were utilized.
RESULTS: Patients were treated with a relatively low median dose of 30 Gy in 3 fractions. Fractions were generally delivered once weekly. Median biologically effective dose (BED) was 60 Gy, and the median gross tumor volume (GTV) was 12.16 cc. Median follow-up was 7.36 months. 1-year local control was 75% via the Kaplan-Meier method. On follow-up imaging, 43%, 40%, and 17% of lesions were decreased, stable, and increased in size, respectively. 1-year OS was 46% and varied by primary tumor, with median OS of 34.3, 25.1, 12.5, and 4.6 months for ovarian, breast, colorectal, and lung primary tumors, respectively. Breast and ovarian primary patients had better OS (p < 0.0001), and lung primary patients had worse OS (p = 0.032). Higher BED values, the number of hepatic lesions, and larger GTV were not predictive of local control, radiographic response, or OS. 21% of patients suffered from treatment toxicity, but no grade ≥3 toxicity was reported.
CONCLUSION: Relatively low-dose SBRT for liver metastases demonstrated efficacy and minimal toxicity, even for patients with large tumors or multiple lesions. This approach may be useful for patients in whom higher-dose therapy is contraindicated or associated with high risk for toxicity. OS depends largely on the primary tumor.
© 2020 Published by Elsevier B.V. on behalf of Greater Poland Cancer Centre.

Entities:  

Keywords:  Dose-fractionation; Liver; Metastasis; SABR; SBRT

Year:  2020        PMID: 33100916      PMCID: PMC7578529          DOI: 10.1016/j.rpor.2020.09.010

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  34 in total

1.  Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies.

Authors:  Karyn A Goodman; Ellen A Wiegner; Katherine E Maturen; Zhigang Zhang; Qianxing Mo; George Yang; Iris C Gibbs; George A Fisher; Albert C Koong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-28       Impact factor: 7.038

2.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.

Authors:  Y Fong; J Fortner; R L Sun; M F Brennan; L H Blumgart
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

3.  Serological diagnostic factors for liver metastasis in patients with colorectal cancer.

Authors:  Xiong-Zhi Wu; Feng Ma; Xue-Lin Wang
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

4.  Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results.

Authors:  Giovanni Ambrosino; Francesco Polistina; Giorgio Costantin; Paolo Francescon; Rosabianca Guglielmi; Pierluigi Zanco; Franco Casamassima; Antonio Febbraro; Giorgio Gerunda; Franco Lumachi
Journal:  Anticancer Res       Date:  2009-08       Impact factor: 2.480

5.  Analysis of radiation-induced liver disease using the Lyman NTCP model.

Authors:  Laura A Dawson; Daniel Normolle; James M Balter; Cornelius J McGinn; Theodore S Lawrence; Randall K Ten Haken
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-07-15       Impact factor: 7.038

6.  Resection of hepatic metastases from colorectal cancer.

Authors:  M A Adson; J A van Heerden; M H Adson; J S Wagner; D M Ilstrup
Journal:  Arch Surg       Date:  1984-06

7.  Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients.

Authors:  H Blomgren; I Lax; I Näslund; R Svanström
Journal:  Acta Oncol       Date:  1995       Impact factor: 4.089

8.  Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer.

Authors:  Marta Scorsetti; Tiziana Comito; Angelo Tozzi; Pierina Navarria; Antonella Fogliata; Elena Clerici; Pietro Mancosu; Giacomo Reggiori; Lorenza Rimassa; Guido Torzilli; Stefano Tomatis; Armando Santoro; Luca Cozzi
Journal:  J Cancer Res Clin Oncol       Date:  2014-09-23       Impact factor: 4.553

9.  Analysis of clinical complication data for radiation hepatitis using a parallel architecture model.

Authors:  A Jackson; R K Ten Haken; J M Robertson; M L Kessler; G J Kutcher; T S Lawrence
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-02-15       Impact factor: 7.038

10.  Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach.

Authors:  Tiziana Comito; Luca Cozzi; Elena Clerici; Maria Concetta Campisi; Rocco Luca Emanuele Liardo; Pierina Navarria; AnnaMaria Ascolese; Angelo Tozzi; Cristina Iftode; Fiorenza De Rose; Elisa Villa; Nicola Personeni; Lorenza Rimassa; Armando Santoro; Antonella Fogliata; Pietro Mancosu; Stefano Tomatis; Marta Scorsetti
Journal:  BMC Cancer       Date:  2014-08-27       Impact factor: 4.430

View more
  1 in total

Review 1.  Stereotactic radiotherapy for liver oligometastases.

Authors:  Claudia Menichelli; Franco Casamassima; Cynthia Aristei; Gianluca Ingrosso; Simona Borghesi; Fabio Arcidiacono; Valentina Lancellotta; Ciro Franzese; Stefano Arcangeli
Journal:  Rep Pract Oncol Radiother       Date:  2022-03-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.